Axonics, Inc. (NASDAQ:AXNX) Shares Bought by Slotnik Capital LLC

Slotnik Capital LLC boosted its stake in shares of Axonics, Inc. (NASDAQ:AXNX) by 15.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 115,186 shares of the company’s stock after buying an additional 15,402 shares during the period. Axonics accounts for 2.7% of Slotnik Capital LLC’s investment portfolio, making the stock its 12th largest position. Slotnik Capital LLC’s holdings in Axonics were worth $8,017,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its stake in Axonics by 637.7% during the first quarter. Janus Henderson Group PLC now owns 178,322 shares of the company’s stock worth $12,298,000 after buying an additional 154,149 shares during the last quarter. Cowen AND Company LLC purchased a new stake in Axonics in the second quarter valued at $605,000. Bank of New York Mellon Corp raised its position in Axonics by 12.0% in the second quarter. Bank of New York Mellon Corp now owns 218,171 shares of the company’s stock valued at $14,668,000 after purchasing an additional 23,460 shares during the period. Rhumbline Advisers raised its position in Axonics by 13.7% in the second quarter. Rhumbline Advisers now owns 78,401 shares of the company’s stock valued at $5,271,000 after purchasing an additional 9,446 shares during the period. Finally, Wolverine Asset Management LLC raised its position in Axonics by 22.0% in the second quarter. Wolverine Asset Management LLC now owns 42,191 shares of the company’s stock valued at $2,836,000 after purchasing an additional 7,610 shares during the period. Institutional investors and hedge funds own 99.48% of the company’s stock.

Axonics Stock Performance

AXNX stock opened at $70.98 on Friday. The business’s fifty day moving average price is $70.28 and its 200 day moving average price is $68.83. Axonics, Inc. has a 12-month low of $55.09 and a 12-month high of $71.05. The company has a market capitalization of $3.63 billion, a PE ratio of -591.45 and a beta of 0.82.

Insiders Place Their Bets

In other Axonics news, CFO Kari Leigh Keese sold 2,961 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $69.41, for a total transaction of $205,523.01. Following the sale, the chief financial officer now owns 40,362 shares in the company, valued at $2,801,526.42. This represents a 6.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.85% of the stock is owned by company insiders.

Analysts Set New Price Targets

Separately, Needham & Company LLC restated a “hold” rating on shares of Axonics in a research report on Friday, November 8th. Eight analysts have rated the stock with a hold rating, According to MarketBeat, Axonics currently has an average rating of “Hold” and a consensus price target of $71.00.

Axonics Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.